Eli Lilly | LLY - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
AbbVie USD 12.59B 180M 2025-12
Abbott USD 10.57B 171M 2025-12
ALKERMES USD 407.63M 73.6M 2026-03
Amgen USD 9.14B 432M 2026-03
AstraZeneca USD 17.88B 1.17B 2026-03
Baxter International USD 1.7B 310M 2026-03
Biogen USD 1.79B 76.6M 2026-03
Bristol-Myers Squibb USD 14.36B 164M 2026-03
Coherus Biosciences USD 18.42M 232.08M 2025-12
Drreddys Laboratories INR 1.41B 11.6M 2025-12
Eli Lilly USD 21.18B 1.02B 2026-03
Gilead Sciences USD 4.74B 172M 2026-03
GlaxoSmithKline GBP 7.94B 178M 2026-03
Glaxosmithkline GBP 10.45B 707.81M 2025-12
J&J USD 21.33B 3.72B 2025-12
Medtronic USD 6.36B 30M 2025-12
Merck USD 11.78B 345M 2025-12
Neurocrine Biosciences USD 768.1M 81.3M 2026-03
Novartis USD 9.6B 2.69B 2026-03
Novartis USD 12.29B 3.3B 2025-12
Novo Nordisk DKK 106.26B 11.21B 2026-03
Perrigo USD 697.1M 84.3M 2026-03
Pfizer USD 16.17B 332M 2026-03
Phibro Animal Health USD 215.87M 2.02M 2025-12
Prestige Brands USD 191.92M 1.46M 2026-03
Regeneron Pharmaceuticals USD 5.73B 10.1M 2026-03
Roche Holding CHF 11.9B 460M 2025-12
Sanofi EUR 482M 85M 2026-03
Sanofi EUR 397M 186.13M 2025-12
United Therapeutics USD 312M 38.2M 2026-03
Zoetis USD 1.51B 84M 2026-03